1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
David A. Braun, MD, PhD
Medical Oncology, Genitourinary Oncology
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Biography
David A. Braun, MD, PhD, specializes in medical oncology and hematology, focusing on the treatment of kidney cancers.
As an assistant professor of medicine at Yale School of Medicine, Dr. Braun is dedicated to advancing the understanding and application of immune therapies in kidney cancer.
Immune therapy is a treatment that helps the body’s own defense system, the immune system, fight cancer. Normally, the immune system might not recognize cancer cells because they can disguise themselves. Immune therapy works by removing the "brakes" that prevent the immune system from attacking cancer, allowing it to better target and destroy cancer cells.
Dr. Braun’s research involves exploring how the environment around kidney cancer cells affects treatment and finding specific targets on cancer cells to develop personalized therapies for diseases like renal cell carcinoma.
Dr. Braun received his doctoral degree in computational biology from New York University and his medical degree from the Icahn School of Medicine at Mount Sinai. He completed his residency at Brigham and Women's Hospital and a fellowship in adult oncology through the Dana-Farber/Partners Cancer Care program.
Titles
- Associate Professor of Internal Medicine (Medical Oncology and Hematology)
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- R37 MERIT Award: National Institutes of Health / National Cancer Institute (NIH/NCI) (2023)
- Idea Development Award: Department of Defense (2023)
- Young Physician-Scientist Award: American Society of Clinical Investigation (ASCI) (2023)
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Saleh M, Saad E, Machaalani M, Meli K, Masri J, Malik R, Kane H, Saliby R, Labaki C, Baroud T, Barrios P, Ascione L, Khatoun W, Yekeduz E, Signoretti S, Gusev A, Van Allen E, Braun D, Choueiri T. LIF expression as a predictive biomarker in metastatic renal cell carcinoma. Journal Of Clinical Oncology 2026, 44: 4548-4548. DOI: 10.1200/jco.2026.44.16_suppl.4548.
- Nafeh G, Khatoun W, Masri J, Nawfal R, Machaalani M, Sarout S, Ibrahim E, Baroud T, Ascione L, Barrios P, Eid M, Chehade R, Saleh M, Bian W, Xu W, Braun D, Choueiri T. Association of GFPT2 expression with clinical outcomes in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2026, 44: e16543-e16543. DOI: 10.1200/jco.2026.44.16_suppl.e16543.
- Braun DA, Noel MS, Moy RH, Demel K, Gutierrez M, Sharma S, Hussain A, Gadgeel S, Peguero J, Choueiri TK, Emamekhoo H, Van Tine B, Balaraman R, Elliott G, Nath S, Daigle SR, Kumar P, Scheuber A, Sommerhalder D. HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. Cell Reports Medicine 2026, 102789. DOI: 10.1016/j.xcrm.2026.102789.
- Motzer R, Albiges L, Aguirre S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arija J, Tykodi S, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun D, Powles T, Choueiri T. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Annals Of Oncology 2026 PMID: 41720427, DOI: 10.1016/j.annonc.2026.02.011.
- Ito K, Braun D. Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma. Journal Of Clinical Investigation 2026, 136: e201599. PMID: 41623175, PMCID: PMC12867149, DOI: 10.1172/jci201599.
- Ramasubramanian T, Adstamongkonkul P, Scribano C, Johnson C, Caenepeel S, Hrycyniak L, Vedder L, Dana N, Baltes C, Browning V, Chen Y, Dietz T, Flietner E, Kaplewski N, Kellner A, Korrer M, Liu C, Marhefke N, McDonnell P, Nasreen A, Pope V, Prasad A, Richardson J, Schneider S, Schultz M, Sood C, Sunil A, Euw E, Wait E, Wargowski E, Advani P, Broome B, Bruckbauer A, Godwin A, Kokabi N, Lou Y, Martin R, Robaina M, Toia G, Routh J, Friedl A, Eliceiri K, Szulczewski M, Johnson S, Oliner J, Galon J, Capitini C, Mukhopadhyay D, Taube J, Braun D, Gierman H. A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity. Journal Of Translational Medicine 2026, 24: 18. PMID: 41484629, PMCID: PMC12763878, DOI: 10.1186/s12967-025-07378-2.
- McKay R, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins M, Bangs R, Beckermann K, Bellmunt J, Berg S, Bilen M, Braun D, Carlo M, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi A, Hammers H, Heng D, Hirsch M, Iyer G, Jonasch E, Koshkin V, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott D, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar S, Suarez C, Tang C, Tripathi A, Van Der Heijden M, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri T. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA A Cancer Journal For Clinicians 2025, 76: e70052. PMID: 41389316, PMCID: PMC12701758, DOI: 10.3322/caac.70052.
- Savion-Gaiger N, Considine B, Hasson N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M, Hurwitz M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. The Oncologist 2025, 30: oyaf387. PMID: 41287461, PMCID: PMC12704413, DOI: 10.1093/oncolo/oyaf387.
- Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaBi K, Kashima S, Camp S, Meli K, Saad E, Titchen B, Labaki C, Bakouny Z, Pimenta E, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka J, Choueiri T, Braun D, Van Allen E. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 2025, 58: 2814-2829.e9. PMID: 41175876, PMCID: PMC12616721, DOI: 10.1016/j.immuni.2025.10.013.
- Yochum Z, Braun D. Nivolumab and cabozantinib combination therapy demonstrates sustained efficacy in metastatic renal-cell carcinoma. Annals Of Oncology 2025, 37: 13-16. PMID: 41176229, DOI: 10.1016/j.annonc.2025.10.1238.
- Frey A, Clulo K, Fei Y, Dumit T, Scallo F, Allen J, Chang E, Perry C, Wirth L, Jacobs D, Braun D, Bosenberg M, Tran T, Clune J, Kluger H, Olino K, Ishizuka J. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports 2025, 44: 116359. PMID: 41042672, PMCID: PMC12646823, DOI: 10.1016/j.celrep.2025.116359.
- Rout R, Kashima S, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 24TGF-Beta alters CD8+ T cell phenotype and drives resistance to immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.025. PMCID: PMC12509635, DOI: 10.1093/oncolo/oyaf276.025.
- Burns E, Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Atkins M, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 31Lymphocyte heat shock signature predicts response to immune checkpoint blockade in renal cell carcinoma. The Oncologist 2025, 30: oyaf276.032. PMCID: PMC12509613, DOI: 10.1093/oncolo/oyaf276.032.
- Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 41Single-cell dissection of immunosuppressive myeloid subclusters driving resistance to immune checkpoint therapy in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.042. PMCID: PMC12509592, DOI: 10.1093/oncolo/oyaf276.042.
- Saleh M, Saad E, Barrios P, Machaalani M, Ascione L, Khatoun W, Masri J, Chehade R, Eid M, Nawfal R, Semaan K, Yekeduz E, Steiner C, Bian W, Sun M, Signoretti S, Van Allen E, Braun D, Gusev A, Choueri T. 39Intratumoral viral transcriptomic signatures stratify immune phenotypes and clinical outcomes in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.040. PMCID: PMC12509656, DOI: 10.1093/oncolo/oyaf276.040.
- Bohac C, Pal S, Sweis R, Kotecha R, Runcie K, Bilen M, Braun D, Tykodi S, Hoimes C, Suri V, Kanodia J, Salama E, Woo J, Li L, Yang Y, Franklin R, Maly J, Grigg C, Gulati S, VanderWeele D, Garmezy B. 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433). The Oncologist 2025, 30: oyaf276.018. PMCID: PMC12509653, DOI: 10.1093/oncolo/oyaf276.018.
- McKay R, Dugan A, Jariwala U, Ronski K, Mercer J, Saad E, Masri J, Machaalani M, Saleh M, Rose C, Sun M, Signoretti S, Braun D, Pal S, Choueri T. 6Lower checkpoint gene expression is associated with primary resistance to nivolumab-ipilimumab combination in advanced renal cell carcinoma. The Oncologist 2025, 30: oyaf276.007. PMCID: PMC12509601, DOI: 10.1093/oncolo/oyaf276.007.
- Xu W, Xie W, Liu F, Birch G, Welch C, Nguyen M, Stanojevic M, Viswanathan S, McGregor B, Ritz J, Braun D, Nikiforow S, Romee R, Choueri T. 19A phase 0 pilot study of memory-like natural killer (NK) cell immune therapy in patients with renal cell carcinoma or urothelial carcinoma (NCT06318871). The Oncologist 2025, 30: oyaf276.020. PMCID: PMC12509657, DOI: 10.1093/oncolo/oyaf276.020.
- Tang C, Poduval D, Rout R, Lee S, Panian J, Saidian A, McKay R, Braun D. 40Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.041. PMCID: PMC12509631, DOI: 10.1093/oncolo/oyaf276.041.
- Albiges L, Motzer R, Aguirre S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Angel J, Arija A, Tykodi S, Ma H, Zhou L, van Kooten Losio M, Simmons A, Braun D, Choueri T, Powles T. 22Final results of the phase 3 COSMIC-313 study comparing first-line cabozantinib plus nivolumab and ipilimumab with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma. The Oncologist 2025, 30: oyaf276.023. PMCID: PMC12509622, DOI: 10.1093/oncolo/oyaf276.023.
- Simsek B, Paul M, Xie W, Ahmar N, Matar S, Laimon Y, Oliveira G, Mohanna R, Delcea A, Choueri T, Braun D, Sun M, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Freeman G, Wu C, McDermott D, Atkins M, Signoretti S. 4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial. The Oncologist 2025, 30: oyaf276.005. PMCID: PMC12509661, DOI: 10.1093/oncolo/oyaf276.005.
- Madsen K, Soulati H, Mortiz V, Braun D. 25Determining the impact of HIF2α inhibition on T cell function in clear cell renal cell carcinoma. The Oncologist 2025, 30: oyaf276.026. PMCID: PMC12509585, DOI: 10.1093/oncolo/oyaf276.026.
- Quijano E, Martinez-Saucedo D, Ianniello Z, Pinto-Medici N, Rackear M, Chen H, Lola-Pereira L, Liu Y, Hegan D, Shan X, Tseng R, Yugawa D, Chowdhury S, Khang M, Singh J, Abdullah R, Azhir P, Kashima S, Woods W, Gosstola N, Turner B, Squinto S, Ludwig D, Bindra R, Robert M, Braun D, Perez Pinera P, Saltzman W, Escobar-Hoyos L, Glazer P. Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer. Science Translational Medicine 2025, 17: eadk1868-eadk1868. PMID: 40668891, PMCID: PMC12375925, DOI: 10.1126/scitranslmed.adk1868.
- Labaki C, Saad E, Madsen K, Hobeika C, Bi K, Alchoueiry M, Camp S, Hou Y, Bakouny Z, Matar S, Ahmar N, Nyman J, Zhang L, Priolo C, Rout R, Daou M, Khabibullin D, Salem S, Schindler N, Saliby R, Meli K, Wells J, Pimenta E, Takemura K, Park J, Eid M, Semaan K, Fu J, Denize T, Chehade R, Machaalani M, Nawfal R, Khatoun W, Saleh M, Masri J, Haddad N, Xu W, McGregor B, Hirsch M, Xie W, Heng D, McDermott D, Signoretti S, Van Allen E, Shukla S, Choueiri T, Henske E, Braun D. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. Journal Of Clinical Oncology 2025, 43: 2639-2654. PMID: 40601888, PMCID: PMC13060539, DOI: 10.1200/jco-25-00234.
- Yochum Z, Braun D. Immunotherapy for Renal Cell Carcinoma—What More is to Come? Targeted Oncology 2025, 20: 467-483. PMID: 40208564, DOI: 10.1007/s11523-025-01143-7.
- Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025, 188: 1807-1827.e34. PMID: 40023154, PMCID: PMC11988688, DOI: 10.1016/j.cell.2025.01.046.
- Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma. Cancer Discovery 2025, 15: 948-968. PMID: 39992403, PMCID: PMC12048281, DOI: 10.1158/2159-8290.cd-24-0991.
- Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.
- Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.
- Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.
- Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon Y, Eid M, Sheshdeh A, Krajewski K, Büttner F, Schwab M, Heng D, Casellas R, Rai K, Zacharias Millward N, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri T, Braun D, Shukla S. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nature Cancer 2025, 6: 372-384. PMID: 39789182, PMCID: PMC12121501, DOI: 10.1038/s43018-024-00896-w.
- Iorgulescu J, Blewett T, Xiong K, Crnjac A, Liu R, Sridhar S, Braun D, Sellars M, Cheng J, Rhoades J, Reardon D, Makrigiorgos G, Wu C, Adalsteinsson V. Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients. Clinical Chemistry 2025, 71: 215-225. PMID: 39749509, PMCID: PMC12363414, DOI: 10.1093/clinchem/hvae178.
- Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.
- Yochum Z, Braun D. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. The Lancet 2024, 404: 1280-1282. PMID: 39284326, DOI: 10.1016/s0140-6736(24)01866-x.
- Figiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, Milowsky M, Mitchell T, Bryant R, Sfakianos J, Lamb A. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology 2024, 87: 8-14. PMID: 39227262, DOI: 10.1016/j.eururo.2024.08.025.
- Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 43: 971-982. PMID: 39169264, PMCID: PMC11912513, DOI: 10.1038/s41587-024-02348-3.
- El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen C, Alva A, Fahey C, Beckermann K, Karam J, Campbell M, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney H, De Giorgi U, Parikh O, Winquist E, Master V, Garcia A, Cutuli H, Ferguson T, Gross-Goupil M, Baca S, Pal S, Braun D, McKay R, Heng D, Choueiri T. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. European Urology 2024, 86: 503-512. PMID: 39147674, DOI: 10.1016/j.eururo.2024.07.016.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?Bakouny Z, Braun D, Reznik E, Hakimi A. PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy? EBioMedicine 2024, 105: 105218. PMID: 38924842, PMCID: PMC11259692, DOI: 10.1016/j.ebiom.2024.105218.
- El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, PMCID: PMC11929466, DOI: 10.1016/j.celrep.2024.114350.
- Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, Braun D, Chen Y. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society Of Clinical Oncology Educational Book 2024, 44: e438658. PMID: 38875505, DOI: 10.1200/edbk_438658.
- Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.
- Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
- Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
- Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, Bagheri A, Savla V, Nabil Laimon Y, Gupta S, Vemula S, Braun D, Burke K, Catalano P, Freeman G, Motzer R, Atkins M, McDermott D, Sharpe A, Choueiri T, Signoretti S. PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. Clinical Cancer Research 2024, 30: 803-813. PMID: 38060202, PMCID: PMC10922154, DOI: 10.1158/1078-0432.ccr-23-2274.
- Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.
- Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
- McKay R, Leucht K, Xie W, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. The Oncologist 2023, 29: 324-331. PMID: 37950901, PMCID: PMC10994246, DOI: 10.1093/oncolo/oyad298.
- Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, Hari S, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun D, Rodig S, Choueiri T, Signoretti S, Van Allen E. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Reports Medicine 2023, 4: 101189. PMID: 37729872, PMCID: PMC10518628, DOI: 10.1016/j.xcrm.2023.101189.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Henske E, Cheng L, Hakimi A, Choueiri T, Braun D. Chromophobe renal cell carcinoma. Cancer Cell 2023, 41: 1383-1388. PMID: 37541245, DOI: 10.1016/j.ccell.2023.07.006.
- Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.
- Labaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
- Anderson K, Braun D, Buqué A, Gitto S, Guerriero J, Horton B, Keenan B, Kim T, Overacre-Delgoffe A, Ruella M, Triplett T, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For ImmunoTherapy Of Cancer 2023, 11: e006533. PMID: 37399356, PMCID: PMC10314654, DOI: 10.1136/jitc-2022-006533.
- Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.
- Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.
- Saliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.
- Braun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.
- Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.
- Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
- Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, Fonseca M, Spisak S, El Zarif T, Tisza V, Braun D, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar S, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck J, O’Connor E, Bell C, Nuzzo P, Mary Lee G, Signoretti S, Hirsch M, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri T, Kwiatkowski D, Freedman M. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications 2023, 14: 346. PMID: 36681680, PMCID: PMC9867739, DOI: 10.1038/s41467-023-35833-5.
- Groha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: ccr.22.0923. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Oliveira G, Stromhaug K, Cieri N, Iorgulescu J, Klaeger S, Wolff J, Rachimi S, Chea V, Krause K, Freeman S, Zhang W, Li S, Braun D, Neuberg D, Carr S, Livak K, Frederick D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon C, Keskin D, Ott P, Rodig S, Boland G, Wu C. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022, 605: 532-538. PMID: 35508657, PMCID: PMC9815755, DOI: 10.1038/s41586-022-04682-5.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait. The New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Hollenhorst M, Braun D, Burtner C, Cajigas I, Cunningham-Bussel A, Eser P, Nabel C, Tsai F, Weeks L, Michel T, Yialamas M. Bridging the Divide: Student Grand Rounds at the Interface of Basic Science and Clinical Medicine. Academic Medicine 2020, 95: 548-552. PMID: 31833852, PMCID: PMC9357424, DOI: 10.1097/acm.0000000000003116.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- Varshney A, Braun D, Patel A, Yialamas M. What was old is new again: learning from the modern master clinician. The Clinical Teacher 2018, 16: 274-276. PMID: 30125460, DOI: 10.1111/tct.12919.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Locations
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
Biography
David A. Braun, MD, PhD, specializes in medical oncology and hematology, focusing on the treatment of kidney cancers.
As an assistant professor of medicine at Yale School of Medicine, Dr. Braun is dedicated to advancing the understanding and application of immune therapies in kidney cancer.
Immune therapy is a treatment that helps the body’s own defense system, the immune system, fight cancer. Normally, the immune system might not recognize cancer cells because they can disguise themselves. Immune therapy works by removing the "brakes" that prevent the immune system from attacking cancer, allowing it to better target and destroy cancer cells.
Dr. Braun’s research involves exploring how the environment around kidney cancer cells affects treatment and finding specific targets on cancer cells to develop personalized therapies for diseases like renal cell carcinoma.
Dr. Braun received his doctoral degree in computational biology from New York University and his medical degree from the Icahn School of Medicine at Mount Sinai. He completed his residency at Brigham and Women's Hospital and a fellowship in adult oncology through the Dana-Farber/Partners Cancer Care program.
Titles
- Associate Professor of Internal Medicine (Medical Oncology and Hematology)
Education & Training
- InstructorHarvard Medical School (2021)
- PhysicianDana-Farber Cancer Institute (2021)
- Postdoctoral FellowDana-Farber Cancer Institute / Harvard Medical School (2019)
- Chief Medical ResidentBrigham and Women’s Hospital / Harvard Medical School (2017)
- Clinical FellowDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women’s Hospital / Harvard Medical School (2016)
- ResidentBrigham and Women’s Hospital / Harvard Medical School (2015)
- InternBrigham and Women’s Hospital / Harvard Medical School (2014)
- MDIcahn School of Medicine at Mount Sinai (2013)
- PhDCourant Institute of Mathematical Sciences at New York University, Computational Biology (2012)
- ABPrinceton University, Molecular Biology (2006)
Additional Information
Honors & Recognitions
- R37 MERIT Award: National Institutes of Health / National Cancer Institute (NIH/NCI) (2023)
- Idea Development Award: Department of Defense (2023)
- Young Physician-Scientist Award: American Society of Clinical Investigation (ASCI) (2023)
- Trailblazer Award: Kidney Cancer Association (2022)
- Goodman and Gilman Yale Scholar: Yale School of Medicine (2022)
- Spatial Multiomics Award: Akoya Biosciences (2021)
- Sparkathon: Emerging Leaders Igniting Innovation: Society for Immunotherapy of Cancer (SITC) (2021)
- 1st Runner-Up, Clinician Scientist: Immuno-Oncology Young Investigator Forum (2021)
- Next Gen Innovator Award: HemOnc Today (2019)
- John R. Svenson Fellowship: Dana-Farber Cancer Institute (2019)
Board Certifications
- AB of Internal Medicine, Medical Oncology (2020)
- AB of Internal Medicine, Internal Medicine (2016)
Professional Service
- European Society for Medical Oncology (ESMO) Scientific Committee for Investigational Immunotherapy Track (2022): Member
- Kidney Caner Association Think Tank (2021): Participant
- Department of Defense Congressionally Directed Medical Research Program Scientific Review Panel (2020 - 2021): Member
- Kidney Cancer Research Summit Steering Committee (2019 - 2020): Committee Member
- Hoosier Cancer Research Network Correlative Science Clinical Trial Working Group (2019 - Present): Member
- American Physician Scientist Association (2009 - 2010): President
Publications
- Saleh M, Saad E, Machaalani M, Meli K, Masri J, Malik R, Kane H, Saliby R, Labaki C, Baroud T, Barrios P, Ascione L, Khatoun W, Yekeduz E, Signoretti S, Gusev A, Van Allen E, Braun D, Choueiri T. LIF expression as a predictive biomarker in metastatic renal cell carcinoma. Journal Of Clinical Oncology 2026, 44: 4548-4548. DOI: 10.1200/jco.2026.44.16_suppl.4548.
- Nafeh G, Khatoun W, Masri J, Nawfal R, Machaalani M, Sarout S, Ibrahim E, Baroud T, Ascione L, Barrios P, Eid M, Chehade R, Saleh M, Bian W, Xu W, Braun D, Choueiri T. Association of GFPT2 expression with clinical outcomes in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2026, 44: e16543-e16543. DOI: 10.1200/jco.2026.44.16_suppl.e16543.
- Braun DA, Noel MS, Moy RH, Demel K, Gutierrez M, Sharma S, Hussain A, Gadgeel S, Peguero J, Choueiri TK, Emamekhoo H, Van Tine B, Balaraman R, Elliott G, Nath S, Daigle SR, Kumar P, Scheuber A, Sommerhalder D. HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results. Cell Reports Medicine 2026, 102789. DOI: 10.1016/j.xcrm.2026.102789.
- Motzer R, Albiges L, Aguirre S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Arija J, Tykodi S, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun D, Powles T, Choueiri T. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Annals Of Oncology 2026 PMID: 41720427, DOI: 10.1016/j.annonc.2026.02.011.
- Ito K, Braun D. Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma. Journal Of Clinical Investigation 2026, 136: e201599. PMID: 41623175, PMCID: PMC12867149, DOI: 10.1172/jci201599.
- Ramasubramanian T, Adstamongkonkul P, Scribano C, Johnson C, Caenepeel S, Hrycyniak L, Vedder L, Dana N, Baltes C, Browning V, Chen Y, Dietz T, Flietner E, Kaplewski N, Kellner A, Korrer M, Liu C, Marhefke N, McDonnell P, Nasreen A, Pope V, Prasad A, Richardson J, Schneider S, Schultz M, Sood C, Sunil A, Euw E, Wait E, Wargowski E, Advani P, Broome B, Bruckbauer A, Godwin A, Kokabi N, Lou Y, Martin R, Robaina M, Toia G, Routh J, Friedl A, Eliceiri K, Szulczewski M, Johnson S, Oliner J, Galon J, Capitini C, Mukhopadhyay D, Taube J, Braun D, Gierman H. A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity. Journal Of Translational Medicine 2026, 24: 18. PMID: 41484629, PMCID: PMC12763878, DOI: 10.1186/s12967-025-07378-2.
- McKay R, Pal S, Xie W, Aggen D, Albiges L, Apolo A, Atkins M, Bangs R, Beckermann K, Bellmunt J, Berg S, Bilen M, Braun D, Carlo M, Efstathiou J, Galsky M, Grivas P, Gupta S, Haas N, Hakimi A, Hammers H, Heng D, Hirsch M, Iyer G, Jonasch E, Koshkin V, Kryvenko O, Lewis B, Li R, Matin S, Maughan B, McDermott D, McGregor B, Meeks J, Milowsky M, Motzer R, Necchi A, Petrylak D, Porten S, Powles T, Rini B, Shuch B, Siefker-Radtke A, Sonpavde G, Sridhar S, Suarez C, Tang C, Tripathi A, Van Der Heijden M, Voss M, Xu W, Zhang T, Rosenberg J, Choueiri T. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers. CA A Cancer Journal For Clinicians 2025, 76: e70052. PMID: 41389316, PMCID: PMC12701758, DOI: 10.3322/caac.70052.
- Savion-Gaiger N, Considine B, Hasson N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M, Hurwitz M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. The Oncologist 2025, 30: oyaf387. PMID: 41287461, PMCID: PMC12704413, DOI: 10.1093/oncolo/oyaf387.
- Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinomaBi K, Kashima S, Camp S, Meli K, Saad E, Titchen B, Labaki C, Bakouny Z, Pimenta E, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka J, Choueiri T, Braun D, Van Allen E. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 2025, 58: 2814-2829.e9. PMID: 41175876, PMCID: PMC12616721, DOI: 10.1016/j.immuni.2025.10.013.
- Yochum Z, Braun D. Nivolumab and cabozantinib combination therapy demonstrates sustained efficacy in metastatic renal-cell carcinoma. Annals Of Oncology 2025, 37: 13-16. PMID: 41176229, DOI: 10.1016/j.annonc.2025.10.1238.
- Frey A, Clulo K, Fei Y, Dumit T, Scallo F, Allen J, Chang E, Perry C, Wirth L, Jacobs D, Braun D, Bosenberg M, Tran T, Clune J, Kluger H, Olino K, Ishizuka J. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports 2025, 44: 116359. PMID: 41042672, PMCID: PMC12646823, DOI: 10.1016/j.celrep.2025.116359.
- Rout R, Kashima S, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 24TGF-Beta alters CD8+ T cell phenotype and drives resistance to immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.025. PMCID: PMC12509635, DOI: 10.1093/oncolo/oyaf276.025.
- Burns E, Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Atkins M, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 31Lymphocyte heat shock signature predicts response to immune checkpoint blockade in renal cell carcinoma. The Oncologist 2025, 30: oyaf276.032. PMCID: PMC12509613, DOI: 10.1093/oncolo/oyaf276.032.
- Kashima S, Rout R, Hugaboom M, Ye Z, Schindler N, Dighe A, Sun M, Lee G, Xu W, Signoretti S, McGregor B, McKay R, Choueri T, Braun D. 41Single-cell dissection of immunosuppressive myeloid subclusters driving resistance to immune checkpoint therapy in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.042. PMCID: PMC12509592, DOI: 10.1093/oncolo/oyaf276.042.
- Saleh M, Saad E, Barrios P, Machaalani M, Ascione L, Khatoun W, Masri J, Chehade R, Eid M, Nawfal R, Semaan K, Yekeduz E, Steiner C, Bian W, Sun M, Signoretti S, Van Allen E, Braun D, Gusev A, Choueri T. 39Intratumoral viral transcriptomic signatures stratify immune phenotypes and clinical outcomes in renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.040. PMCID: PMC12509656, DOI: 10.1093/oncolo/oyaf276.040.
- Bohac C, Pal S, Sweis R, Kotecha R, Runcie K, Bilen M, Braun D, Tykodi S, Hoimes C, Suri V, Kanodia J, Salama E, Woo J, Li L, Yang Y, Franklin R, Maly J, Grigg C, Gulati S, VanderWeele D, Garmezy B. 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433). The Oncologist 2025, 30: oyaf276.018. PMCID: PMC12509653, DOI: 10.1093/oncolo/oyaf276.018.
- McKay R, Dugan A, Jariwala U, Ronski K, Mercer J, Saad E, Masri J, Machaalani M, Saleh M, Rose C, Sun M, Signoretti S, Braun D, Pal S, Choueri T. 6Lower checkpoint gene expression is associated with primary resistance to nivolumab-ipilimumab combination in advanced renal cell carcinoma. The Oncologist 2025, 30: oyaf276.007. PMCID: PMC12509601, DOI: 10.1093/oncolo/oyaf276.007.
- Xu W, Xie W, Liu F, Birch G, Welch C, Nguyen M, Stanojevic M, Viswanathan S, McGregor B, Ritz J, Braun D, Nikiforow S, Romee R, Choueri T. 19A phase 0 pilot study of memory-like natural killer (NK) cell immune therapy in patients with renal cell carcinoma or urothelial carcinoma (NCT06318871). The Oncologist 2025, 30: oyaf276.020. PMCID: PMC12509657, DOI: 10.1093/oncolo/oyaf276.020.
- Tang C, Poduval D, Rout R, Lee S, Panian J, Saidian A, McKay R, Braun D. 40Investigating the determinants of immunotherapy response in the primary tumor of clear cell renal cell carcinoma (RCC). The Oncologist 2025, 30: oyaf276.041. PMCID: PMC12509631, DOI: 10.1093/oncolo/oyaf276.041.
- Albiges L, Motzer R, Aguirre S, Kanesvaran R, Centkowski P, Reimers M, Sade J, Pouessel D, Biscaldi E, Esteban E, Angel J, Arija A, Tykodi S, Ma H, Zhou L, van Kooten Losio M, Simmons A, Braun D, Choueri T, Powles T. 22Final results of the phase 3 COSMIC-313 study comparing first-line cabozantinib plus nivolumab and ipilimumab with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma. The Oncologist 2025, 30: oyaf276.023. PMCID: PMC12509622, DOI: 10.1093/oncolo/oyaf276.023.
- Simsek B, Paul M, Xie W, Ahmar N, Matar S, Laimon Y, Oliveira G, Mohanna R, Delcea A, Choueri T, Braun D, Sun M, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Freeman G, Wu C, McDermott D, Atkins M, Signoretti S. 4CD163+ Tumor-Associated macrophages and clinical outcomes to First-Line nivolumab therapy in patients with metastatic clear cel renal cell carcinoma: insights from the HCRN GU16-260 trial. The Oncologist 2025, 30: oyaf276.005. PMCID: PMC12509661, DOI: 10.1093/oncolo/oyaf276.005.
- Madsen K, Soulati H, Mortiz V, Braun D. 25Determining the impact of HIF2α inhibition on T cell function in clear cell renal cell carcinoma. The Oncologist 2025, 30: oyaf276.026. PMCID: PMC12509585, DOI: 10.1093/oncolo/oyaf276.026.
- Quijano E, Martinez-Saucedo D, Ianniello Z, Pinto-Medici N, Rackear M, Chen H, Lola-Pereira L, Liu Y, Hegan D, Shan X, Tseng R, Yugawa D, Chowdhury S, Khang M, Singh J, Abdullah R, Azhir P, Kashima S, Woods W, Gosstola N, Turner B, Squinto S, Ludwig D, Bindra R, Robert M, Braun D, Perez Pinera P, Saltzman W, Escobar-Hoyos L, Glazer P. Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer. Science Translational Medicine 2025, 17: eadk1868-eadk1868. PMID: 40668891, PMCID: PMC12375925, DOI: 10.1126/scitranslmed.adk1868.
- Labaki C, Saad E, Madsen K, Hobeika C, Bi K, Alchoueiry M, Camp S, Hou Y, Bakouny Z, Matar S, Ahmar N, Nyman J, Zhang L, Priolo C, Rout R, Daou M, Khabibullin D, Salem S, Schindler N, Saliby R, Meli K, Wells J, Pimenta E, Takemura K, Park J, Eid M, Semaan K, Fu J, Denize T, Chehade R, Machaalani M, Nawfal R, Khatoun W, Saleh M, Masri J, Haddad N, Xu W, McGregor B, Hirsch M, Xie W, Heng D, McDermott D, Signoretti S, Van Allen E, Shukla S, Choueiri T, Henske E, Braun D. Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma. Journal Of Clinical Oncology 2025, 43: 2639-2654. PMID: 40601888, PMCID: PMC13060539, DOI: 10.1200/jco-25-00234.
- Yochum Z, Braun D. Immunotherapy for Renal Cell Carcinoma—What More is to Come? Targeted Oncology 2025, 20: 467-483. PMID: 40208564, DOI: 10.1007/s11523-025-01143-7.
- Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, Nabilsi N, Kramer N, Forman C, Lippincott I, Klaeger S, Phulphagar K, Chea V, Kim N, Vanasse A, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani E, Stevens J, Lane W, Camp S, Meli K, Pappalardi M, Herbert Z, Qiu X, Cejas P, Long H, Shukla S, Van Allen E, Choueiri T, Churchman L, Abelin J, Gurer C, MacBeath G, Childs R, Carr S, Keskin D, Wu C, Kaelin W. HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. Cell 2025, 188: 1807-1827.e34. PMID: 40023154, PMCID: PMC11988688, DOI: 10.1016/j.cell.2025.01.046.
- Hugaboom M, Wirth L, Street K, Ruthen N, Jegede O, Schindler N, Shah V, Zaemes J, El Ahmar N, Matar S, Savla V, Choueiri T, Denize T, West D, McDermott D, Plimack E, Sosman J, Haas N, Stein M, Alter R, Bilen M, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma. Cancer Discovery 2025, 15: 948-968. PMID: 39992403, PMCID: PMC12048281, DOI: 10.1158/2159-8290.cd-24-0991.
- Braun D, Moranzoni G, Chea V, McGregor B, Blass E, Tu C, Vanasse A, Forman C, Forman J, Afeyan A, Schindler N, Liu Y, Li S, Southard J, Chang S, Hirsch M, LeBoeuf N, Olive O, Mehndiratta A, Greenslade H, Shetty K, Klaeger S, Sarkizova S, Pedersen C, Mossanen M, Carulli I, Tarren A, Duke-Cohan J, Howard A, Iorgulescu J, Shim B, Simon J, Signoretti S, Aster J, Elagina L, Carr S, Leshchiner I, Getz G, Gabriel S, Hacohen N, Olsen L, Oliveira G, Neuberg D, Livak K, Shukla S, Fritsch E, Wu C, Keskin D, Ott P, Choueiri T. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 2025, 639: 474-482. PMID: 39910301, PMCID: PMC11903305, DOI: 10.1038/s41586-024-08507-5.
- Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, Bratslavsky G, Braun D, Brugarolas J, Choueiri T, Finelli A, George D, Haas N, Hakimi A, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan W, Master V, McGregor B, McKay R, Mehra R, Pal S, Poteat S, Powles T, Rossi S, Shapiro D, Signoretti S, Singer E, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart G. A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types. European Urology 2025, 87: 385-389. PMID: 39855942, DOI: 10.1016/j.eururo.2025.01.007.
- Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler N, Labaki C, Saliby R, Dinh K, Horst J, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee G, Hurwitz M, McGregor B, Hirsch M, Shukla S, McDermott D, Signoretti S, Romee R, Choueiri T, Braun D. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 2025, 10: 104105. PMID: 39813824, PMCID: PMC11783098, DOI: 10.1016/j.esmoop.2024.104105.
- Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon Y, Eid M, Sheshdeh A, Krajewski K, Büttner F, Schwab M, Heng D, Casellas R, Rai K, Zacharias Millward N, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri T, Braun D, Shukla S. Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma. Nature Cancer 2025, 6: 372-384. PMID: 39789182, PMCID: PMC12121501, DOI: 10.1038/s43018-024-00896-w.
- Iorgulescu J, Blewett T, Xiong K, Crnjac A, Liu R, Sridhar S, Braun D, Sellars M, Cheng J, Rhoades J, Reardon D, Makrigiorgos G, Wu C, Adalsteinsson V. Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients. Clinical Chemistry 2025, 71: 215-225. PMID: 39749509, PMCID: PMC12363414, DOI: 10.1093/clinchem/hvae178.
- Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024, 10: e184545. PMID: 39561007, PMCID: PMC11721305, DOI: 10.1172/jci.insight.184545.
- Yochum Z, Braun D. Rechallenging with anti-PD-1 therapy in advanced renal cell carcinoma. The Lancet 2024, 404: 1280-1282. PMID: 39284326, DOI: 10.1016/s0140-6736(24)01866-x.
- Figiel S, Bates A, Braun D, Eapen R, Eckstein M, Manley B, Milowsky M, Mitchell T, Bryant R, Sfakianos J, Lamb A. Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology. European Urology 2024, 87: 8-14. PMID: 39227262, DOI: 10.1016/j.eururo.2024.08.025.
- Cieri N, Hookeri N, Stromhaug K, Li L, Keating J, Díaz-Fernández P, Gómez-García de Soria V, Stevens J, Kfuri-Rubens R, Shao Y, Kooshesh K, Powell K, Ji H, Hernandez G, Abelin J, Klaeger S, Forman C, Clauser K, Sarkizova S, Braun D, Penter L, Kim H, Lane W, Oliveira G, Kean L, Li S, Livak K, Carr S, Keskin D, Muñoz-Calleja C, Ho V, Ritz J, Soiffer R, Neuberg D, Stewart C, Getz G, Wu C. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation. Nature Biotechnology 2024, 43: 971-982. PMID: 39169264, PMCID: PMC11912513, DOI: 10.1038/s41587-024-02348-3.
- El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen C, Alva A, Fahey C, Beckermann K, Karam J, Campbell M, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney H, De Giorgi U, Parikh O, Winquist E, Master V, Garcia A, Cutuli H, Ferguson T, Gross-Goupil M, Baca S, Pal S, Braun D, McKay R, Heng D, Choueiri T. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. European Urology 2024, 86: 503-512. PMID: 39147674, DOI: 10.1016/j.eururo.2024.07.016.
- Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.
- PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?Bakouny Z, Braun D, Reznik E, Hakimi A. PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy? EBioMedicine 2024, 105: 105218. PMID: 38924842, PMCID: PMC11259692, DOI: 10.1016/j.ebiom.2024.105218.
- El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, PMCID: PMC11929466, DOI: 10.1016/j.celrep.2024.114350.
- Ali M, Eid M, Saliby R, Choi S, McKay R, Siva S, Braun D, Chen Y. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy. American Society Of Clinical Oncology Educational Book 2024, 44: e438658. PMID: 38875505, DOI: 10.1200/edbk_438658.
- Saliby R, Labaki C, Jammihal T, Xie W, Sun M, Shah V, Saad E, Kane M, Kashima S, Sadak K, El Zarif T, Poduval D, Motzer R, Powles T, Rini B, Albiges L, Pal S, McGregor B, McKay R, Signoretti S, Van Allen E, Shukla S, Choueiri T, Braun D. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 2024, 42: 732-735. PMID: 38579722, PMCID: PMC11130783, DOI: 10.1016/j.ccell.2024.03.002.
- Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.
- Wang Y, Cho J, Kastrunes G, Buck A, Razimbaud C, Culhane A, Sun J, Braun D, Choueiri T, Wu C, Jones K, Nguyen Q, Zhu Z, Wei K, Zhu Q, Signoretti S, Freeman G, Hemberg M, Marasco W. Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model. IScience 2024, 27: 108879. PMID: 38327771, PMCID: PMC10847687, DOI: 10.1016/j.isci.2024.108879.
- Denize T, Jegede O, Matar S, El Ahmar N, West D, Walton E, Bagheri A, Savla V, Nabil Laimon Y, Gupta S, Vemula S, Braun D, Burke K, Catalano P, Freeman G, Motzer R, Atkins M, McDermott D, Sharpe A, Choueiri T, Signoretti S. PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. Clinical Cancer Research 2024, 30: 803-813. PMID: 38060202, PMCID: PMC10922154, DOI: 10.1158/1078-0432.ccr-23-2274.
- Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.
- Choueiri T, Donahue A, Braun D, Rini B, Powles T, Haanen J, Larkin J, Mu X, Pu J, Teresi R, di Pietro A, Robbins P, Motzer R. Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma. Cancer Discovery 2023, 14: of1-of18. PMID: 38385846, PMCID: PMC10905671, DOI: 10.1158/2159-8290.cd-23-0680.
- McKay R, Leucht K, Xie W, Jegede O, Braun D, Atkins M, Grimm M, Choueiri T. A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. The Oncologist 2023, 29: 324-331. PMID: 37950901, PMCID: PMC10994246, DOI: 10.1093/oncolo/oyad298.
- Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, Hari S, Rosenthal J, Mehta N, Jiang B, Sharma B, Felt K, Umeton R, Braun D, Rodig S, Choueiri T, Signoretti S, Van Allen E. Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. Cell Reports Medicine 2023, 4: 101189. PMID: 37729872, PMCID: PMC10518628, DOI: 10.1016/j.xcrm.2023.101189.
- Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
- Henske E, Cheng L, Hakimi A, Choueiri T, Braun D. Chromophobe renal cell carcinoma. Cancer Cell 2023, 41: 1383-1388. PMID: 37541245, DOI: 10.1016/j.ccell.2023.07.006.
- Schindler N, Braun D. Antigenic targets in clear cell renal cell carcinoma. Kidney Cancer 2023, 7: 81-91. PMID: 38014393, PMCID: PMC10475986, DOI: 10.3233/kca-230006.
- Labaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.
- Anderson K, Braun D, Buqué A, Gitto S, Guerriero J, Horton B, Keenan B, Kim T, Overacre-Delgoffe A, Ruella M, Triplett T, Veeranki O, Verma V, Zhang F. Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Journal For ImmunoTherapy Of Cancer 2023, 11: e006533. PMID: 37399356, PMCID: PMC10314654, DOI: 10.1136/jitc-2022-006533.
- Saliby R, Saad E, Labaki C, Xu W, Braun D, Viswanathan S, Bakouny Z. Novel Targeted Therapies for Renal Cell Carcinoma Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition. Hematology/Oncology Clinics Of North America 2023, 37: 1015-1026. PMID: 37385938, DOI: 10.1016/j.hoc.2023.05.022.
- Saad E, Saliby R, Labaki C, Xu W, Viswanathan S, Braun D, Bakouny Z. Novel Immune Therapies for Renal Cell Carcinoma Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes. Hematology/Oncology Clinics Of North America 2023, 37: 1027-1040. PMID: 37391289, DOI: 10.1016/j.hoc.2023.05.023.
- Saliby R, Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane M, Madsen K, Ficial M, Hirsch L, Wei X, Steinharter J, Harshman L, Vaishampayan U, Severgnini M, McDermott D, Lee G, Xu W, Van Allen E, McGregor B, Signoretti S, Choueiri T, McKay R, Braun D. Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research 2023, 11: 1114-1124. PMID: 37279009, PMCID: PMC10526700, DOI: 10.1158/2326-6066.cir-22-0996.
- Braun D, Chakraborty A. Immunobiology and Metabolic Pathways of Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 827-840. PMID: 37246090, DOI: 10.1016/j.hoc.2023.04.012.
- Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.
- Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.
- Nassar A, Abou Alaiwi S, Baca S, Adib E, Corona R, Seo J, Fonseca M, Spisak S, El Zarif T, Tisza V, Braun D, Du H, He M, Flaifel A, Alchoueiry M, Denize T, Matar S, Acosta A, Shukla S, Hou Y, Steinharter J, Bouchard G, Berchuck J, O’Connor E, Bell C, Nuzzo P, Mary Lee G, Signoretti S, Hirsch M, Pomerantz M, Henske E, Gusev A, Lawrenson K, Choueiri T, Kwiatkowski D, Freedman M. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nature Communications 2023, 14: 346. PMID: 36681680, PMCID: PMC9867739, DOI: 10.1038/s41467-023-35833-5.
- Groha S, Alaiwi S, Xu W, Naranbhai V, Nassar A, Bakouny Z, El Zarif T, Saliby R, Wan G, Rajeh A, Adib E, Nuzzo P, Schmidt A, Labaki C, Ricciuti B, Alessi J, Braun D, Shukla S, Keenan T, Van Allen E, Awad M, Manos M, Rahma O, Zubiri L, Villani A, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl K, Freedman M, Choueiri T, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nature Medicine 2022, 28: 2584-2591. PMID: 36526723, PMCID: PMC10958775, DOI: 10.1038/s41591-022-02094-6.
- Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, Lyu H, Morriss J, Garcia Z, Murray E, Reardon D, Yoon C, Braun D, Livak K, Wu C, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 2022, 55: 1940-1952.e5. PMID: 36223726, PMCID: PMC9745674, DOI: 10.1016/j.immuni.2022.09.002.
- Denize T, Hou Y, Pignon J, Walton E, West D, Freeman G, Braun D, Wu C, Gupta S, Motzer R, Atkins M, McDermott D, Choueiri T, Shukla S, Signoretti S. Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research 2022, 28: ccr.22.0923. PMID: 35802667, PMCID: PMC9481706, DOI: 10.1158/1078-0432.ccr-22-0923.
- Oliveira G, Stromhaug K, Cieri N, Iorgulescu J, Klaeger S, Wolff J, Rachimi S, Chea V, Krause K, Freeman S, Zhang W, Li S, Braun D, Neuberg D, Carr S, Livak K, Frederick D, Fritsch E, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon C, Keskin D, Ott P, Rodig S, Boland G, Wu C. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 2022, 605: 532-538. PMID: 35508657, PMCID: PMC9815755, DOI: 10.1038/s41586-022-04682-5.
- Braun DA, Wu CJ. Tumor-Infiltrating T Cells — A Portrait. The New England Journal Of Medicine 2022, 386: 992-994. PMID: 35263526, DOI: 10.1056/nejmcibr2119477.
- Tsai F, Guercio B, Stuver S, Stern R, Peluso M, Winkler M, Piawah S, Vallurupalli M, Luskin M, Braun D, Parent A, Glotzbecker B, Kilbridge K. Resident-Reported Impact of a Novel Oncology Curriculum for Internal Medicine Residents. Journal Of Cancer Education 2021, 37: 1879-1885. PMID: 34480712, PMCID: PMC8417651, DOI: 10.1007/s13187-021-02055-6.
- Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 2021, 39: 632-648.e8. PMID: 33711273, PMCID: PMC8138872, DOI: 10.1016/j.ccell.2021.02.013.
- Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology 2021, 18: 199-214. PMID: 33437048, PMCID: PMC8317018, DOI: 10.1038/s41571-020-00455-z.
- Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, Lichtenstein L, Neuberg D, Catalano P, Freeman GJ, Sharpe AH, McDermott DF, Van Allen EM, Signoretti S, Wu CJ, Shukla SA, Choueiri TK. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine 2020, 26: 909-918. PMID: 32472114, PMCID: PMC7499153, DOI: 10.1038/s41591-020-0839-y.
- Hollenhorst M, Braun D, Burtner C, Cajigas I, Cunningham-Bussel A, Eser P, Nabel C, Tsai F, Weeks L, Michel T, Yialamas M. Bridging the Divide: Student Grand Rounds at the Interface of Basic Science and Clinical Medicine. Academic Medicine 2020, 95: 548-552. PMID: 31833852, PMCID: PMC9357424, DOI: 10.1097/acm.0000000000003116.
- Bakouny Z, Flippot R, Braun D, Lalani A, Choueiri T. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus 2019, 6: 37-40. PMID: 30827939, DOI: 10.1016/j.euf.2019.02.014.
- Iorgulescu J, Braun D, Oliveira G, Keskin D, Wu C. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine 2018, 10: 87. PMID: 30466478, PMCID: PMC6249768, DOI: 10.1186/s13073-018-0598-2.
- Varshney A, Braun D, Patel A, Yialamas M. What was old is new again: learning from the modern master clinician. The Clinical Teacher 2018, 16: 274-276. PMID: 30125460, DOI: 10.1111/tct.12919.
- Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.
- Braun D, Burke K, Van Allen E. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research 2016, 22: 5642-5650. PMID: 27698000, PMCID: PMC5135569, DOI: 10.1158/1078-0432.ccr-16-0066.
Locations
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511
1
Prostate and Urologic Cancers Program
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl 4
New Haven, CT 06511
1 of 2
- Prostate and Urologic Cancers ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 4New Haven, CT 06511
- Melanoma ProgramSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 8New Haven, CT 06511